News

Keya medical's plaque analysis and FFR-CT reports generated from a single CT scan.

The company now has multiple FDA-cleared algorithms for evaluating CCTA results.

Pi-Cardia ShortCut TAVR device

The FDA-cleared ShortCut leaflet modification device has been linked to positive real-world outcomes.

These "forward-thinking organizations" have all committed to participating in multiple data registries and quality improvement programs. Did your facility make the cut? 

Roderick Tung explains cardio-neuro ablation therapy for recurrent vasovagal syncope

The procedure is designed to help patients who experience frequent fainting episodes that impair their quality of life.

Medicare Advantage

"These high costs could pose barriers to care for such plans’ beneficiaries,” researchers wrote July 1 in the American Journal of Roentgenology

cybersecurity cyberattack hack hackers lock protection

The feds cautioned that exploitation of these vulnerabilities could allow attackers to write files, access unauthorized information, or crash client servers. 

Stravitz Sanyal Institute for Liver Disease and Metabolic Health at VCU

The Stravitz Sanyal Institute for Liver Disease and Metabolic Health at VCU seeks to develop new treatments that could help the millions of individuals impacted by these ailments. 

surgeon

With Election Day only four months away, healthcare is again emerging as a major source of idealistic campaign promises. Many of these are driven by widespread public angst. What sorts of changes can U.S. healthcare stakeholders realistically expect once the results are in? 

RadNet CEO Howard Berger

This comes after RadNet executed several acquisitions so far this year, including buying French AI firm Gleamer for approximately $270 million. 

morgue

The United States appears to be leading all high-income countries in an unfortunate, distinctly undesirable statistical category. 

New ultrasound needle yielded more substantial tissue samples

Vibrating at up to 30,000 times per second, the sonographic device helps tissue to detach more easily without inflicting a large puncture wound to collect an adequate amount of tissue.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.

Around the web

The company now has multiple FDA-cleared algorithms for evaluating CCTA results.

The FDA-cleared ShortCut leaflet modification device has been linked to positive real-world outcomes.

These "forward-thinking organizations" have all committed to participating in multiple data registries and quality improvement programs. Did your facility make the cut?